Accomplishments

BPCA has led to more than 150 drugs/therapeutics and 50 conditions/indications prioritized for further study. It has also led to more than 30 clinical trials funded to improve the knowledge of medicines used in children.

BPCA activities have produced nine label changes to improve pediatric labeling (dosage, safety, and/or efficacy information). View a selection of approved labels on the U.S. Food and Drug Administration (FDA) website.

The first label change was for the drug propylthiouracil. NICHD sponsored a workshop in October 2008 that reviewed epidemiology and adverse event data that showed a 10-fold risk of liver damage in patients treated with this drug. Based on the results of this meeting, the FDA issued a "Dear Doctor" letter to health care professionals on June 4, 2009, outlining the risk of serious liver injury with the use of this drug in adult and pediatric patients. 

The second label change was for the drug pralidoxime. Based on BPCA prioritization, this drug was relabeled for pediatric use in September 2010.

Sodium nitroprusside was relabeled in December 2013 for pediatric use based on BPCA-sponsored pharmacokinetic (PK), safety, and efficacy trials. View the FDA Sodium Nitroprusside Label (PDF 65.9 KB) for more information.

Meropenem was relabeled in December 2014 for the treatment of pediatric intra-abdominal infections based on BPCA-sponsored PK, safety, and efficacy trials. View the FDA Meropenem Label (PDF 225 KB) for more information.

Mercy Tape, a weight estimation device for children ages 2-16 years, was the BPCA’s first device label, approved in May 2015.

In response to results from a BPCA-funded Pediatric Trials Network study, Lisinopril was relabeled in April 2016 to treat hypertension in children with renal transplants.

Lorazepam was relabeled in June 2016 based on BPCA-sponsored PK, safety, and efficacy trials. View the FDA Lorazepam Label (PDF 303 KB) for more information.

Lithium was relabeled in October 2018 based on BPCA-sponsored clinical trials that evaluated the dosing as well as the short and long-term safety and effectiveness of lithium to treat bipolar disease in children. View the FDA Lithium Label (PDF 344 KB) for more information.

Acyclovir was relabeled in January 2019 for use in neonates up to 3 months old, based on an observational, retrospective study that included analysis of safety data. View the approval of the new FDA Acyclovir Label (PDF 513 KB) for more information.

Based on BPCA research, four additional studies have been submitted to the FDA for label change consideration and are currently pending final review: ampicillin dosing in neonates; diazepam dosing and safety in children; doxycycline dosing in children; and bactrim dosing and safety in children.  

top of pageBACK TO TOP